Australia markets closed

Orexo AB (publ) (ORXOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.75000.0000 (0.00%)
At close: 03:40PM EDT

Orexo AB (publ)

P.O. Box 303
Uppsala 751 05
Sweden
46 1 87 80 88 00
https://www.orexo.com

Sector(s):Β Healthcare
Industry:Β Drug Manufacturersβ€”Specialty & Generic
Full-time employees:Β 123

Key executives

NameTitlePayExercisedYear born
Mr. Nikolaj SorensenPres & CEON/AN/A1972
Mr. Joseph DeFeoExec. VP & CFON/AN/A1961
Ms. Cecilia CouplandSr. VP & Head of OperationsN/AN/A1976
Lena WangeInvestor Relations & Communications DirectorN/AN/AN/A
Dr. Michael Sumner M.D.Chief Medical OfficerN/AN/A1965
Mr. Robert RonnSr. VP and Head of R&DN/AN/A1976
Mr. Dennis UrbaniakExec. VP of Digital TherapeuticsN/AN/A1969
Mr. Robert A. DelucaPres of Orexo US IncN/AN/A1961
Mr. Jesper LindAdvisorN/AN/A1960
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, Europe, and the United Kingdom. Its products include Zubsolv tablets for the treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of short-term insomnia. The company's development products comprise OX124, a medication for naloxone rescue; OX125, a medication for nalmefene rescue; OX640, a medication for allergic reactions; and OX338 sublingual tablet formulation of ketorolac for treatment of moderate to severe pain. It is also developing OX-MPI program for the treatment of microvascular diseases in chronic inflammatory conditions. The company's digital therapies comprise deprexis therapy for the treatment of mild to severe depression; vorvida for alcohol use disorder; and modia for opioid use disorder. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.

Corporate governance

Orexo AB (publ)’s ISS governance QualityScore as of 1 May 2022 is 2. The pillar scores are Audit: 8; Board: 1; Shareholder rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.